Table 3. Predictors of TIRFI after TAVR procedure.
| Variable | Univariable Analysis | Multivariable Analysis | ||
|---|---|---|---|---|
| OR (95% CI) | P value | OR (95% CI) | P value | |
| Age, years | 0.98 (0.95–1.00) | 0.13 | - | - |
| Male sex | 0.84 (0.59–1.19) | 0.32 | - | - |
| NYHA class III/IV | 1.11 (0.69–1.76) | 0.67 | - | - |
| Diabetes | 0.76 (0.52–1.11) | 0.15 | - | - |
| Hypertension | 1.09 (0.74–1.63) | 0.65 | - | - |
| COPD | 1.01 (0.65–1.56) | 0.98 | - | - |
| Pulmonary hypertension | 0.77 (0.51–1.16) | 0.20 | - | - |
| CAD | 0.73 (0.51–1.04) | 0.077 | 0.69 (0.48–0.98) | 0.039 |
| Peripheral vascular disease | 1.13 (0.72–1.78) | 0.60 | - | - |
| Previous CABG | 0.96 (0.62–1.46) | 0.83 | - | - |
| STS score, % | 1.00 (0.98–1.03) | 0.45 | - | - |
| eGFR, mL/min/1.73m2 | 0.98 (0.96–0.99) | 0.014 | 0.98 (0.97–1.00) | 0.008 |
| Diuretics | 1.15 (0.80–1.64) | 0.46 | - | - |
| ACE inhibitors or ARB | 1.27 (0.90–1.79) | 0.18 | - | - |
| Beta-blockers | 1.06 (0.75–1.51) | 0.73 | - | - |
| Statin | 0.96 (0.68–1.37) | 0.83 | - | - |
| LVEF, % | 0.99 (0.98–1.00) | 0.45 | - | - |
| Mean transaortic gradient, mmHg | 1.00 (0.99–1.02) | 0.10 | - | - |
| AVA, cm2 | 1.68 (0.64–4.38) | 0.28 | - | - |
| Contrast media volume, mL | 1.00 (0.99–1.00) | 0.71 | - | - |
| Procedure access (except Transfemoral) | 0.58 (0.27–1.25) | 0.16 | - | - |
| Prosthetic valve type | - | 0.55 | - | - |
| Corevalve | 1.00 | - | - | - |
| Sapien XT | 1.00 (0.67–1.51) | - | - | - |
| Inovare prosthesis | 0.54 (0.18–1.68) | - | - | - |
| Period of TAVR procedure | 0.25 | - | - | |
| T1 (2008–2010) | 1.00 | - | - | - |
| T2 (2011–2013) | 0.87 (0.54–1.38) | - | - | - |
| T3 (2014–2015) | 1.24 (0.72–2.14) | - | - | - |
95% CI, 95% confidence interval.
Abbreviations: ACE indicates angiotensin-converting enzyme; ARB, angiotensin receptor blocker; AVA, aortic valve area; CABG, coronary artery bypass graft; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular filtration rate; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; OR, odds ratio; STS, Society of Thoracic Surgeons; TAVR, transcatheter aortic valve replacement; TIRFI, TAVR induced renal function improvement.